Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04174820
Other study ID # 49RC18_0010
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 12, 2020
Est. completion date November 1, 2022

Study information

Verified date November 2020
Source University Hospital, Angers
Contact Denise Jolivot, MD
Phone 33-(0)2-41-35-58-08
Email DeJolivot@chu-angers.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

One of the major complications of posterior fossa surgery is Posterior Fossa Syndrome (PFS). This syndrome is due to a possible complication of surgical excision of a tumor of the cerebellum (4th ventricle) and is characterized by transient postoperative mutism, dysarthria, behavioral, and affective disorders, as well as motor disorders. PFS is thought to be related to axonal lesions. The long-term consequences on the cognitive and psychosocial sphere of PFS have been widely documented. On the other hand, the literature concerning the consequences of this syndrome on language is much restricted. Beyond the language, the role of cerebellum would be central in cognition, some authors even comparing it to a great "conductor" who would underlie the learning of most motor and cognitive automatisms.


Description:

The physiopathology and the anatomo-functional correlates of motor, cognitive, and language functions after surgery of PF tumors are still rare and little known. The objective of this study is to analyze them via morphometric MRI analysis and functional and structural connectivity in children away from PF surgery, coupled with clinical data analysis.


Recruitment information / eligibility

Status Recruiting
Enrollment 145
Est. completion date November 1, 2022
Est. primary completion date November 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Years to 17 Years
Eligibility Inclusion Criteria: - Patient with a low grade glioma of the posterior fossa or a medulloblastoma - Healthy volunteers without any tumor in the posterior fossa (control case) - At one year of the last treatment for the retrospective groups, or patient who have an indication to a surgery of a tumor of the posterior fossa - Eligibility to a functional MRI - Informed consent dated and signed by the holder of the parental authority (if minor) or by the patient (if major) to take part in the study - Affiliated to a Social Security scheme Exclusion Criteria: - Antecedent of neurologic, metabolic or genetic disease - Brainstem glioma - Have a contraindication to a MRI

Study Design


Intervention

Other:
Functional Magnetic Resonance Imaging (fMRI)
list of the tests: Box and Blocks test, Nine Hole Peg test, walkway GAITRite, EXALang tests, NEPSY II subtests, BRIEF, FEE, WISC 5 tests

Locations

Country Name City State
France CHU Angers Angers
France Hôpital Necker Paris
France Institut Curie Paris
France Hôpitaux Saint-Maurice Saint-Maurice
France Gustave Roussy Villejuif

Sponsors (3)

Lead Sponsor Collaborator
University Hospital, Angers Assistance Publique - Hôpitaux de Paris, National Cancer Institute, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Structural and functional connectives in brain MRI Review and compare, in MRI, the structural and functional cerebellar-hemispheric connectives. The primary endpoint the analysis of fMRI brain mapping in accordance to the relations with the motor functions (balance and dexterity), cognitive, behavioral/social cognition and language after treatment for a child's posterior fossa tumor (with or without posterior fossa syndrome) and, in comparison with matched control group on age, sex and level study. The MRI data will be the subject of a specific statistical treatment, via dedicated software, which will be implemented under the control of the investigators who have conducted such an fMRI analysis in previous studies. Various brain mapping can be established from the data collected. It may include statistical comparisons between different preselected regions, and different experimental conditions, or correlation studies between brain activation and clinical parameters. One day
Secondary Dexterity with Box and Blocks test Evaluation of the dexterity with Box and Blocks test (number of displaced blocks with each hand). One day
Secondary Dexterity with Nine Hole Peg test Evaluation of the dexterity with Nine Hole Peg test (sum of time of realization of the test in seconds and number of displaced pegs). One day
Secondary The balance and the walk Evaluation of the balance and the walk with the walkway (time in seconds for the completion of the walkway). One day
Secondary Language functions Evaluation of the language functions with the EXALang tests (lexicology, phonology, oral expression, oral understand, reading ...). One day
Secondary Social cognition functions and the cognitive function: recognition of the affects Evaluation with the NEPSY II subtests (total score of 35). One day
Secondary Social cognition functions and the cognitive function: behavioural executive functions Evaluation with the BRIEF test (86 items for parents). One day
Secondary Social cognition functions and the cognitive function: flexibility Evaluation with the FEE test (completion time and number of errors). One day
Secondary Social cognition functions and the cognitive function: perceptual and verbal reasoning Evaluation with the WISC V test (number of correct answers). One day
Secondary Patients characteristics Age, sociodemographics, personal and cancer history. One day
Secondary Quality of life of patients: PedsQL questionnaire Comparison of score of Quality of Life questionnaire (PedsQL 4.0: Pediatric Quality of Life Inventory Version 4.0 Generic Core Scales) between the four groups of the study. The Quality of Life questionnaire PedsQL 4.0 is composed of 23 items comprising 4 dimensions. Items are reversed scored and linearly transformed to a 0-100 scale. In order to get a total score we must sum all the items scores over the number of items answered on all the scales. If more than 50% of the items in the scale are missing, the scale scores should not be computed. One day
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1